[1] Liaw YF,Kao JH,Piratvisuth T,et al. Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2012update. Hepatol Int,2012,6(3):531-561. [2] Perz JF,Armstrong GL,Farrington LA,et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol,2006,45(4):529-538. [3] Pipili C,Cholongitas E,Papatheodoridis G. Review article:nucleos(t)ide analogues in patients withchronic hepatitis B virus infection and chronic kidney disease. Aliment Pharmacol Ther,2014,39(1):35-46. [4] Tsai MC,Chen CH,Hung CH,et al. A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B:a match-control study. Clin Microbiol Infect,2014,20(2):90-100. [5] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2010年版). 实用肝脏病杂志,2011,14(2):81-89. [6] Qi X,Wang JY,Mao RC,et al. Impact of nucleos(t)ide analogues on the estimated glomerular filtration rate in patients with chronic hepatitis B:a prospective cohort study in China. J Viral Hepat,2015,22(1):46-54. [7] Turan I,Yapali S,Bademkiran F,et al. Telbivudine in liver transplant recipients:Renal protection does not overcome the risk of polyneuropathy and myopathy. Liver Transpl,2015,21(8):1066-1075. [8] Lee S,Park JY,Song K,et al. Comparison of the effects of telbivudine and entecavir treatment on estimated glomerular filtration rate in patients with chronic hepatitis B. Gut Liver,2015,9(6):776-783. [9] Gane EJ,Deray G,Liaw YF,et al. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology, 2014,146(1):138-146.e5. [10] Gara N,Zhao X,Collins MT,et al. Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B. Aliment Pharmacol Ther,2012,35(11):1317-1325. [11] Laprise C,Baril JG,Dufresne S,et al. Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients:results from 10 years of follow-up. Clin Infect Dis,2013,56(4):567-575. [12] Salome T,Kasamba I,Mayanja BN,et al. The effect of tenofovir on renal function among Ugandan adults on long-term antiretroviral therapy:a cross-sectional enrolment analysis. AIDS Res Ther,2016,13(1):28. [13] Jose S,Hamzah L,Campbell LJ,et al. Incomplete reversibility of estimated glomerular filtration rate decline following tenofovir disoproxil fumarate exposure. J Infect Dis,2014,210(3):363-373. [14] Ha NB,Trinh HN,Rosenblatt L,et al. Treatment outcomes with first-line therapies with entecavir and tenofovir in treatment-naive chronic hepatitis B patients in a routine clinical practice. J Clin Gastroenterol,2016,50(2):169-174. [15] Mallet V,Schwarzinger M,Vallet-Pichard A,et al. Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus monoinfection. Clin Gastroenterol Hepatol,2015,13(6):1181-1188,e1. [16] Pradat P,Le Pogam MA,Okon JB,et al. Evolution of glomerular filtrationrate in HIV-infected,HIV-HBV coinfected and HBV- infected patients receiving tenofovir disoproxil fumarate. J Viral Hepat,2013,20(9):650-657. [17] Koklu S,Gulsen MT,Tuna Y,et al. Differences in nephrotoxicity risk and renal effects among anti-viral therapies against hepatitis B. Aliment Pharmacol Ther,2015,41(3):310-319. [18] Lin YS,Shih SC,Wang HY,et al. Comparison of telbivudine and entecavir on the change of off-treatment eGFR after 3 years of treatment in non-cirrhotic chronic hepatitis B patients.BMC Gastroenterol,2017,17(1):22. [19] Tsai MC,Chen CH,Tseng PL,et al. Does nucleos(t)ide analogues treatment affect renal function in chronic hepatitis B patients who have already decreased eGFR A longitudinal study. PLoS One,2016,11(3):e0149761. [20] Levey AS,StevensLA,Schmid CH,et al. A new equation to estimate glomerular filtration rate. Ann Intern Med,2009,150(9):604-612. [21] Hwang HS,Park CW,Song MJ.Tenofovir-associated?Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection.Hepatology,2015,62(4):1318-1320. [22] Conti F,Vitale G,Cursaro C,et al. Tenofovir-induced?Fanconi syndrome in a patient with chronic hepatitis B monoinfection. Ann Hepatol,2016,15(2):273-276. [23] Mauss S,Berger F,Filmann N,et al. Effect of HBV polymerase inhibitors on renal function in patients with chronichepatitis B. J Hepatol,2011,55(6):1235-1240. [24] Ha NB,Ha NB,Garcia RT,et al. Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology,2009,50(3):727-734. [25] Lee S,Park JY,Song K,et al. Comparison of the effects of telbivudine and entecavir treatment on estimated glomerular filtration rate in patients with chronic hepatitis B. Gut Liver,2015,9(6):776-783. [26] Liang KH,Chen YC,Hsu CW,et al. Decrease of serum angiotensin converting enzyme levels upon telbivudine treatment for chronic hepatitis B virus infection and negative correlations between the enzyme levels and estimated glumerular filtration rates. Hepat Mon,2014,14(1):e15074. |